Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). The purpose of this study to see what effect pridopidine has on movement, thinking, and behavior, compared to placebo (a capsule that looks like pridopidine but has no active ingredient), in people with Huntington’s Disease.

Pridopidine, the investigational drug being studied may have an effect on some of the symptoms of Huntington’s Disease that depend on dopamine. Dopamine is a substance that is naturally made by the human body. It is made in many areas of the brain, and affects how people behave, think and move. It has been suggested that changes in the way dopamine works in Huntington’s Disease creates signs and symptoms of the condition. This study is being conducted to determine if pridopidine helps with the signs and symptoms of Huntington’s Disease.

Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN). 400 participants will be enrolled globally at approximately 51 study sites. Participants will receive either pridopidine or placebo for 26 weeks.

Click here for more detailed eligibility information and exclusion criteria.

A randomized, double blind research study to see what effect the investigational drug, pridopidine, has on movement, thinking, and behavior, compared to placebo (a capsule that looks like pridopidine but has no active ingredient), in people with Huntington disease after 26 weeks of receiving either pridopidine or placebo.

What is the Pride-HD Study?

The purpose of this randomized, double blind study is to see what effect the investigational drug, pridopidine, has on movement, thinking, and behavior, compared to placebo, in people with Huntington disease after 26 weeks of receiving either pridopidine or placebo. In addition, information will be collected about safety and tolerability of pridopidine in people with HD.

Who is running the Pride-HD Trial?

Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington Disease Network (EHDN). 400 participants will be enrolled globally at approximately 51 study sites. Participants will receive either pridopidine or placebo for 26 weeks. The study is sponsored by Teva Branded Pharmaceutical Products.

Who is eligible to participate in the Pride-HD trial?

You may be eligible to participate in the study if you meet the following requirements:

• You are over the age of 21
• Have a diagnosis of Huntington disease
• Have a caregiver willing to attend study visits with you
• Have no history of significant heart disease, epilepsy or seizures within the last 5 years, or serious medical illness
• Have not been treated with tetrabenazine within 6 weeks of study screening.

How can I learn more about the Pride-HD trial?

Visit: www.ClinicalTrials.gov